Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04862195
Recruitment Status : Active, not recruiting
First Posted : April 27, 2021
Last Update Posted : April 22, 2022
Sponsor:
Information provided by (Responsible Party):
Blue Note Therapeutics

Brief Summary:

This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and depression symptoms when used adjunctively with multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks.

Study population will consist of up to 553 participants with stage I-III breast cancer or stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10 and secondary endpoints of percent improvement in depressive symptoms will be assessed at Week 12.

An interim analysis for efficacy and futility will be conducted once 236 participants have completed the study.


Condition or disease Intervention/treatment Phase
Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Stage I Lung Cancer AJCC v8 Stage II Lung Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Device: Attune™ Device: Cerena™ Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blinded, Randomized, Adaptive Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices (Attune™ and Cerena™) as Interventions for Physical and Emotional Health in Adjunctive Oncology Treatment
Actual Study Start Date : May 15, 2021
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Active Comparator: Attune™
Attune™ is a completely digital, 10-session, cognitive behavioral therapeutic intervention.
Device: Attune™
Software as a medical device

Active Comparator: Cerena™
Cerena™ is a completely digital, 10-session, health education and wellness intervention.
Device: Cerena™
Software as a medical device




Primary Outcome Measures :
  1. Cancer-related symptoms of anxiety (1) [ Time Frame: Baseline up to Week 10 ]
    Percent reduction in PROMIS-A scores, reduction indicates reduced anxiety


Secondary Outcome Measures :
  1. Cancer-related symptoms of depression (1) [ Time Frame: Baseline up to Week 10 ]
    Percent reduction in PROMIS-D scores, reduction indicates reduced depression

  2. Cancer-related symptoms of anxiety (2) [ Time Frame: Baseline up to Week 12 ]
    Percent reduction in PROMIS-A scores, reduction indicates reduced anxiety

  3. Cancer-related symptoms of anxiety (3) [ Time Frame: Baseline up to Week 10 ]
    Percent reduction in Clinical Global Impression Scale and Improvement scores, reduction indicates reduced anxiety

  4. Cancer-related symptoms of depression (4) [ Time Frame: Baseline up to Week 12 ]
    Percent reduction in Clinical Global Impression Scale and Improvement scores, reduction indicates reduced depression

  5. Mean mHealth App Usability Questionnaire (MAUQ) for Standalone mHealth Apps Used by Patients [ Time Frame: Baseline up to Week 10 ]
    Higher scores indicate higher ease of use / easier to use applications


Other Outcome Measures:
  1. Quality of life via PROMIS-Global Health v1.2 [ Time Frame: Weeks 10 and Week 12 ]
    The PROMIS Global Health measures assess an individual's physical, mental, and social health. The measures are generic, rather than disease-specific, and often use an "In General" item context as it is intended to globally reflect individuals' assessment of their health. The adult PROMIS Global Health measure produces two scores: Physical Health and Mental Health (Promis-Global Health Scoring Manual, 2017). Higher scores for responses always indicate better health.

  2. Patient self-efficacy via the Patient Activation Measure-13 (PAM-13) [ Time Frame: Weeks 10 ]
    Patient Activation Measures-the knowledge, skills, and confidence to manage one's health is associated with improved self-management behaviors in cancer patients. A patient activation measure (PAM) using PAM-13 will be used to assess participant engagement at baseline after PROMIS-A and PROMIS-D are completed and at Week 10. Higher scores indicate higher self-efficacy.

  3. Patient self-efficacy via the Measurement of Current Status (MOCS) Part A and Part B [ Time Frame: Baseline, Week 6, and Week 10 ]
    The Measure of Current Status (MOCS) scale comes from research on the effects of a multi-modal cognitive-behavioral stress management intervention on the psychosocial well-being of cancer patients. The MOCS has two sections. Part A is items measuring participants' current self-perceived status on several skills that are targeted by the intervention: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed. Part B assesses potential "nonspecific effects" of the intervention: feelings of normalcy vs. alienation, sense of cohesiveness with other patients, perceptions of care from persons around them, and a sense of being better off than other cancer patients. All items were framed in such a way that they are sensible to participants in both conditions. MOCS measurements will be taken at Baseline, Week 6, and Week 10. Higher scores indicate higher self-efficacy.

  4. Immune cell transcription [ Time Frame: Baseline up to Week 12 ]
    Analyses will focus on inflammatory gene expression and related gene regulation pathways due to their established relevance for disease progression/recurrence in the aftermath of cancer diagnosis and treatment, and their role in promoting symptoms of depression or anxiety via effects on central nervous system function



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment or have completed initial cancer directed treatments (surgery, radiation, chemotherapy) within the past 3 months;
  • Are experiencing at least moderate anxiety (GAD-7 >10) or mild-to-moderate depression (PHQ-8 score 5-11);
  • Are fluent in English; and
  • Have access to smartphone, or tablet capable of running iOS or Android software.

Exclusion Criteria:

  • Previous history of cancer;
  • <2-yr survival prognosis as determined by treating clinician;
  • Currently participating in investigative CBT trial for treatment of anxiety or depression;
  • Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study;
  • Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics-sponsored study; and
  • PHQ-9 Q9 response >0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of Category 2- "suicidal ideation" at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04862195


Locations
Layout table for location information
United States, California
OPN Healthcare
Glendale, California, United States, 91203
Oncology Physicians Network Healthcare
Los Alamitos, California, United States, 90720
Redlands Oncology
Redlands, California, United States, 92373
United States, Connecticut
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut, United States, 06360
United States, Illinois
Illinios Cancer Care
Peoria, Illinois, United States, 61615-7828
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
Rogel Cancer Center | University of Michigan
Ann Arbor, Michigan, United States, 48109-0944
United States, Montana
SCL Health
Billings, Montana, United States, 59102
United States, New Jersey
New Jersey Center for Cancer Research
Brick, New Jersey, United States, 08724
United States, New York
New York Cancer & Blood Specialists
Port Jefferson Station, New York, United States, 11776
United States, Ohio
Tri-County Hematology and Oncology-Massillon
Massillon, Ohio, United States, 44646
United States, Texas
MD Anderson
Houston, Texas, United States, 77030
United States, Washington
Northwest Medical Specialty
Tacoma, Washington, United States, 98405
Sponsors and Collaborators
Blue Note Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Patricia A Ganz, MD University of California, Los Angeles
Layout table for additonal information
Responsible Party: Blue Note Therapeutics
ClinicalTrials.gov Identifier: NCT04862195    
Other Study ID Numbers: PROT001
First Posted: April 27, 2021    Key Record Dates
Last Update Posted: April 22, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Lung Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases